^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation + IDH2 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug Class:FLT3 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer
    Title:

    Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

    Published date:
    10/29/2020
    Excerpt:
    The authors reviewed cases of patients with FLT3-internal tandem duplication (FLT3-ITD)-mutated AML with concurrent IDH mutations...LIT with FLT3Is in the frontline and R/R settings demonstrated CR and CRi rates of 67% and 28%, respectively.
    DOI:
    10.1002/cncr.33293